1	Improved diagnosis of SARS-CoV-2 by using Nucleoprotein and Spike protein
2	fragment 2 in quantitative dual ELISA tests
3	Carolina De M. Verissimo <sup>1*</sup> ; Carol O'Brien <sup>2</sup> ; Jesús López Corrales <sup>1</sup> ; Amber Dorey <sup>1</sup> ; Krystyna
4	Cwiklinski <sup>1</sup> ; Richard Lalor <sup>1</sup> ; Jack M. Doyle <sup>2</sup> ; Stephen Field <sup>3</sup> ; Claire Masterson <sup>4</sup> ; Eduardo
5	Ribes Martinez <sup>4</sup> ; Gerry Hughes <sup>5,6</sup> ; Colm Bergin <sup>5,6</sup> ; Kieran Walshe <sup>2</sup> ; Bairbre McNicholas <sup>7</sup> ;
6	John G. Laffey <sup>4</sup> ; John P. Dalton <sup>1</sup> ; Colm Kerr <sup>5,6</sup> ; Sean Doyle <sup>2</sup>
7	
8	1- Molecular Parasitology Lab (MPL) - Centre for One Health and Ryan Institute, School of
9	Natural Science, National University of Ireland Galway, Galway, Republic of Ireland.
10	2- Department of Biology - National University of Ireland Maynooth, Maynooth – Ireland.
11 12	3- Clinical Associate Professor (TCD), Medical and Scientific Director, Irish Blood Transfusion Service, Dublin, Ireland.
13	4- School of Medicine, and Regenerative Medicine Institute (REMEDI) at CÚRAM Centre for
14	Research in Medical Devices, Biomedical Sciences Building, National University of Ireland
15	Galway, Galway, Ireland.
16	5- School of Medicine, Trinity College Dublin, College Green, Dublin 2, Ireland.
17	6- Department of Infectious Diseases, St James's Hospital, James's Street, Dublin 8, Ireland.
18	7- Department of Anaesthesia and Intensive Care Medicine, University Hospital Galway,
19	Saolta University Hospital Group, Galway Ireland.
20	
21	*Corresponding author: carolina.verissimo@nuigalway.ie
22	
23	
24	
25	
26	
27	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 28 SUMMARY

The novel Coronavirus, SARS-CoV-2, is the causative agent of the 2020 worldwide 29 coronavirus pandemic. Antibody testing is useful for diagnosing historic infections of a 30 disease in a population. These tests are also a helpful epidemiological tool for predicting how 31 the virus spreads in a community, relating antibody levels to immunity and for assessing herd 32 immunity. In the present study, SARS-CoV-2 viral proteins were recombinantly produced 33 and used to analyse serum from individuals previously exposed, or not, to SARS-CoV-2. The 34 nucleocapsid (Npro) and Spike subunit 2 (S2Frag) proteins were identified as highly 35 immunogenic, although responses to the former were generally greater. These two proteins 36 were used to develop two quantitative ELISA assays that when used in combination resulted 37 in a highly reliable diagnostic test. Npro and S2Frag-ELISAs could detect at least 10% more 38 39 true positive COVID-19 cases than the commercially available ARCHITECT test (Abbott). Moreover, our quantitative ELISAs also show that specific antibodies to SARS-CoV-2 40 41 proteins tend to wane rapidly even in patients that had developed severe disease. As antibody tests complement COVID-19 diagnosis and determine population-level surveillance during 42 this pandemic, the alternative diagnostic we present in this study could play a role in 43 controlling the spread of the virus. 44

45

#### 46 INTRODUCTION

47 SARS-CoV-2 is a newly emerging member of the *Coronaviridae* (CoV) family, responsible for the Coronavirus disease-2019 (COVID-19) pandemic. It was first identified in December 48 2019 in Wuhan, Hubei province, People's Republic of China, after several individuals 49 developed severe pneumonia similar to that caused by SARS-CoV, the virus responsible for 50 the 2003 SARS outbreak in Asia [1, 2]. Person-to-person transmission of the virus resulted in 51 rapid spreading of SARS-CoV-2 worldwide. More than one year later, the World Health 52 Organization (WHO) reported that SARS-CoV-2 was responsible for more than 130 million 53 infections and 2.8 million deaths around the world [3]. 54

SARS-CoV-2 is an enveloped virus that contains a single-stranded positive-sense
RNA. The virus attaches to pulmonary cells via the angiotensin converting enzyme 2 (ACE2) receptor mediated by a glycoprotein expressed on its surface, the Spike protein (Spro) [4].
Fusion of the viral membrane with the lumen of the endosomal membrane leads to

endocytosis, facilitating infection via entry of the viral RNA into the cytosol. During the
intracellular viral life cycle, two large polyproteins, pp1a and pp1ab, are translated. Sixteen
non-structural proteins (nsp) are co-translationally and post-translationally released from
pp1a and pp1ab upon proteolytic activity of two virus proteases, the papain-like protease
(PLpro) and the 3C-like protease. These proteins are responsible for the establishment of the
viral replication and transcription complex (RTC) which is crucial for virus replication inside
the cells [5].

Individuals infected with SARS-CoV-2 can take from one to 14 days to develop
symptoms, which range from mild to severe. Common symptoms associated with infection
include fever, dry cough, tiredness, loss of taste or smell, aches and pains and diarrhoea.
However, infection in a high proportion of individuals can lead to severe acute respiratory
syndrome (SARS) or acute respiratory distress syndrome (ARDS) which usually require
intensive care. The most severe cases can lead to death [6, 7].

Acute COVID-19 diagnosis mainly relies on real-time reverse transcription 72 polymerase chain reaction (qRT-PCR) or RT loop-mediated isothermal amplification (RT-73 LAMP) testing of respiratory secretions [8]. In the context of the recent virus variants, whole 74 genome sequencing can also be performed to determine the sequence of the SARS-CoV-2 75 76 virus in a sample [9]. Antigen-Detecting Rapid Diagnostic Tests (Ag-RDTs) were developed 77 and have been successfully applied to detect the presence of viral antigens, typically using samples from the respiratory tract to increase the sensitivity of the test [10]. Computed 78 79 tomography (CT) scans can also be performed and show bilateral multilobular ground-glass opacities which aid in diagnosis. Part of the strategy to identify those exposed to infection 80 81 and with an established immune response includes serological tests to detect antibodies to SARS-CoV-2. Furthermore, qRT-PCR and serological testing can be used in combination, 82 83 which was demonstrated to significantly increase the viral detection rates [8, 11].

In general, it takes several days for individuals to build an immune response to the virus. Antibodies to SARS-CoV-2 antigens are detectable in less than 40% of patients within one week of the onset of symptoms, but rapidly increase in the following days [12, 13]. Longitudinal studies are necessary to characterize the longevity of the antibodies in convalescent individuals and to determine if these confer protective immunity [13, 14], and more specifically, to identify which antigen(s) this immunity is directed towards [15, 16]. This knowledge is critical to assess the epidemiological context of the COVID-19 pandemic

and for the differentiation between exposed and non-exposed individuals to define the
locality and distribution of infection that can guide pandemic control measures such as social
distancing. It is also important for vaccine design and the evaluation of vaccine candidates.

94 SARS-CoV-2 antibody tests are widely used for surveillance studies to gather information about infectivity of the virus in a population. Existing commercial SARS-CoV-2 95 antibody tests, including enzyme-linked immunosorbent assays (ELISA), chemiluminescence 96 97 immunoassays and lateral flow assays, were developed using specific viral antigens, principally the Nucleocapsid protein (Npro) and the Spike protein (Spro). The manufacturers 98 99 of several commercial tests assert that these tests have sensitivities between 86.3 and 100% 100 and specificities from 97 to 100%. However, recent studies that have evaluated the accuracy 101 of antibody tests for use in seroprevalence surveys have reported reduced sensitivities. For 102 example, Schnurra et al. [17] compared the performance of eight different commercial tests and concluded that at least four of them were slightly less sensitive than specified by the 103 104 manufacturers. Similarly, evaluations made by Public Health England (PHE) found that one in five people with positive results for SARS-CoV-2 in an antibody test used in UK could be 105 106 wrongly told that they had the infection [18, 19]. Considering the highlighted problems with 107 sensitivity and the limited data regarding the immune response of those individuals beyond 108 35 days post-symptom onset, such results need to be carefully interpreted by public health 109 authorities [20].

110 Timely and accurate diagnosis and identification of an immune response to SARS-111 CoV-2 infection is the foundation of efforts to provide appropriate treatment and recommend isolation that ultimately can contain the COVID-19 pandemic. Npro and Spro-based tests 112 113 were observed to react with different sets of sera and, therefore, using a combination of viral antigens to assess the antibody response could represent a strategy to increase the accuracy of 114 115 identifying true positives [17]. In the present study we demonstrate how the current serological diagnosis of SARS-CoV-2 can be improved by using two highly immunogenic 116 117 virus proteins, Npro and the S2 subdomain of Spro (S2Frag), in a dual ELISA test to detect specific antibody responses to the virus. 118

119

#### 120 METHODS

121 Selecting viral antigens

- 122 In the present study, the full length SARS-CoV-2 Spike protein (Spro, ~135 kDa) and four
- different sections, Spike protein fragment 1 (S1frag, 1-686, ~75 kDa), Spike protein fragment
- 124 2 (S2frag, 687-1273, ~54 kDa), the Spike protein fragment 2 prime region (S2Prime, 816-
- 125 1273, ~38 kDa) and the receptor binding domain (RBD, 319-542, ~29 kDa) were selected for
- recombinant expression (Fig 1A and B) (see also [15]). The entire Npro sequence (2-1269; 50
- 127 kDa) was synthesised for recombinant expression (Fig 1C).
- 128

#### 129 Recombinant expression of SARS-CoV-2 proteins in Escherichia coli

- 130 Sequences encoding the spike protein were codon optimized for expression in *Escherichia*
- 131 *coli* and cloned into the pET-28a(+) vector, and into pET-19b for nucleocapsid protein
- 132 (Genscript Biotech). While Npro contains an N-terminal His-Tag followed by an
- 133 enterokinase cleavage site, all other proteins contain a thrombin cleavage site followed by a
- 134 C-terminal His-tag. The synthesized vectors were transformed into BL21 competent *E. coli*
- 135 cells (ThermoFisher Scientific) following the manufacturer's instructions and stored in Luria
- 136 Bertani (LB) broth (Sigma) supplemented with 25% glycerol at -80°C. LB broth
- supplemented with 50 µg/mL kanamycin, or 100 µg/mL ampicillin for Npro, was inoculated
- 138 from the glycerol stock and incubated shaking at 37°C overnight. The culture was then
- diluted in fresh LB broth supplemented with the appropriate antibiotic, incubated at 37°C to
- 140  $OD_{600}$  0.6 and protein expression induced with 1 mM isopropyl- $\beta$ -D-1-thiogalactopyranoside
- 141 (IPTG; ThermoFisher Scientific) for 4 hr at 30°C. For Npro the cultures were induced with
- 142 0.5 mM IPTG for 3 hr at 37°C. Following centrifugation at 10,000 x g for 10 min at 4°C, the
- bacterial pellets were re-suspended in 10 mL ST buffer (10 mM Tris, 150 mM NaCl, pH 8.0)
- 144 and stored at -20  $^{\circ}$ C.
- 145

#### 146 Solubilisation and purification of recombinant SARS-CoV-2 proteins

147 Defrosted pellets were treated with 0.1 mg/mL lysozyme in the presence of 40 mM DTT for

- 148 1 hr on ice. The proteins in inclusion bodies were solubilised according the protocol
- 149 described by Schlager et al. [21] protocol. Firstly, a 1% (w/v) SDS buffer (8 mM Na<sub>2</sub>HPO<sub>4</sub>,
- 150 286 mM NaCl, 1.4 mM KH<sub>2</sub>PO<sub>4</sub>, 2.6 mM KCl, 1% (w/v) SDS, pH 7.4) containing 0.1 mM
- 151 DTT was added to the pellets, which were then sonicated twice for 2 min, 40% amplitude.
- 152 The samples were centrifuged 15,000 x g at 4°C for 30 min and the resulting supernatant was

filtered using 0.45 μm syringe filters. The filtered supernatant containing the soluble
recombinant protein was passed through a pre-equilibrated Ni-NTA beads column (Qiagen).
The column was washed with 30 mL of wash buffer (8 mM Na<sub>2</sub>HPO<sub>4</sub>, 286 mM NaCl, 1.4
mM KH<sub>2</sub>PO<sub>4</sub>, 2.6 mM KCl, 0.1% Sarkosyl (w/v), 40 mM imidazole, pH 7.4), and the
recombinant protein was eluted using 4 mL of elution buffer (8 mM Na<sub>2</sub>HPO<sub>4</sub>, 286 mM
NaCl, 1.4 mM KH<sub>2</sub>PO<sub>4</sub>, 2.6 mM KCl, 0.1% Sarkosyl (w/v), 250 mM imidazole, pH 7.4). The
purified protein was buffer-exchanged into 1x PBS containing 0.05% sarkosyl, pH 7.4.

Recombinant and soluble Npro was extracted from E. coli by sonicating twice for 2 160 min, 20% amplitude (1 g cells: 5 ml lysis buffer (50 mM Tris, 100 mM NaCL, 1 mM EDTA, 161 10% (v/v) glycerol pH 8.0, with 1 mM PMSF and 4  $\mu$ g/mL leupeptin), followed by 162 centrifugation and dialysis into 20 mM H<sub>2</sub>NaPO<sub>4</sub>, 500 mM NaCl, 20 mM imidazole pH 7.4. 163 The samples were centrifuged and filtered using 0.45 µm syringe filters, prior to application 164 to HisTrap HP columns (GE Healthcare) equilibrated in the same buffer. After extensive column 165 166 washing, bound Npro was eluted with 20 mM H<sub>2</sub>NaPO<sub>4</sub>, 500 mM NaCl, 500 mM imidazole pH 7.4. Npro was stored in the elution buffer. 167

Protein concentrations were verified by Bradford Protein Assay (Bio-Rad) and the 168 proteins visualised on 4-20% SDS-PAGE gels (Bio-Rad) stained with Biosafe Coomassie 169 (Bio-Rad) to check purity. To further confirm the expression and purification of the 170 recombinant proteins, Western blots were performed using a monoclonal mouse anti-171 polyhistidine antibody (diluted 1:5,000) (Sigma-Aldrich) as a primary antibody followed by 172 incubation with a secondary antibody alkaline phosphatase or horseradish peroxidase (HRP)-173 174 conjugated goat to mouse-anti-IgG (diluted 1:5000) (Sigma-Aldrich). Furthermore, the veracity of both S2Frag and Npro recombinant proteins was confirmed by high sensitivity 175 protein mass spectrometry analysis using a Q-Exactive mass spectrometer (ThermoFisher) 176 177 prior to use for ELISA development [22].

178

#### 179 Human sera samples

180 Negative controls consisted of a group of 37 serum samples obtained from the Irish Blood

181 Transfusion Service. All the samples were collected prior to SARS-CoV-2 pandemic (2018)

182 and stored at  $-20^{\circ}$ C.

Human serum samples were obtained from St. James's Hospital, Trinity College Dublin with informed consent. The first set comprised 42 serum samples collected from healthcare workers and all individuals were confirmed to have a SARS-CoV-2 infection by qRT-PCR. All individuals developed symptomatic SARS-CoV-2 infection, and four subjects were hospitalized. The group consisted of 29 females and 13 males, ranging from 27 to 64 years old (average 41.5). The samples were obtained between 17 to 40 days post symptoms onset.

A second set consisted of samples collected from 98 healthcare workers with potential 190 exposure to SARS-CoV-2. This group was divided into symptomatic (N=49) and 191 asymptomatic (N= 49) individuals. Of the 49 symptomatic individuals, only four were 192 confirmed to have a SARS-CoV-2 infection by qRT-PCR. One of these individuals was 193 hospitalized and admitted to the Intensive Care Unit (ICU). The other 45 individuals were not 194 tested by qRT-PCR because of the number of days after onset of symptoms >7 days. The 195 symptomatic group consisted of 37 female and 12 male individuals, ranging from 23 to 63 196 years old. The samples were collected between 16 and 113 days after onset of symptoms. The 197 asymptomatic group was formed by 26 females and 23 males, ranging from 22 to 64 years 198 old. Seven individuals in this group were tested doe SARS-CoV-2 infection by qRT-PCR due 199 200 to close contact status tested and were all given negative results.

Plasma samples from individuals hospitalized with or without COVID-19 related 201 symptoms were obtained. This group consisted of 25 patients, 13 females and 12 males 202 (between 35 to 89 years old), and was divided into qRT-PCR positive (N=15) and qRT-PCR 203 204 negative (N=10). The plasma samples were collected between 0 and 65 days after onset of symptoms. Two plasma samples, at different time-points, were obtained and analysed from 205 those 15 qRT-PCR positive patients. Of the 15 positive individuals, seven were admitted to 206 the ICU (2 females and 5 males, ranging from 50 to 73 years old). Seven individuals required 207 208 invasive ventilation. One of the individuals died (male, 79 years old).

Human experimental work was conducted according to Human Research Ethics
Committees. Ethical approval for the healthcare worker serum sample collection and analysis
was granted by the St. James's Hospital and Tallaght University Hospital research ethics
committee in April 2020 (reference 2020-04 List 15) and permit BSRESC-2020-2403204
(Maynooth University Ethics committee). The work conduced with the samples from
hospitalized patients followed the research permit 20-NREC-COV-20 (Galway University

- 215 hospital research ethics committee). All participants provided written informed consent prior
- to the study or assent followed by informed consent once able for patients admitted to the
- 217 ICU where informed consent was not possible.
- 218

#### 219 Western Blot assays

- 220 Purified recombinant proteins (~2.5 μg/lane) were resolved in a 4-20% SDS-PAGE gel
- 221 (BioRad) and transferred on to a nitrocellulose membrane. The membranes were incubated in
- blocking solution (2% BSA-PBST) at 4°C, overnight, then probed with human sera diluted
- 1:100 in 2% BSA-PBST for 1 hr at room temperature. The membrane was washed four times
- in PBST before incubation with the secondary antibody, HRP-conjugated goat anti-Human
- IgG (Fc specific) diluted 1:15000 in 2% BSA-PBST, for 1 hr at RT. The blots were
- developed for 3 min using 3,3'-Diaminobenzidine substrate (DAB, Sigma-Aldrich).
- 227

# 228 Dual antigen SARS-CoV-2 ELISA development

For the dual ELISA tests, separated flat-bottom 96 well microtitre plates (Nunc MaxiSorp,

Biolegend) were coated with either Npro  $(1 \mu g/mL)$  or S2Frag  $(1 \mu g/mL)$  diluted in carbonate

- buffer and incubated overnight at 4°C. The plates were incubated with blocking buffer (2%
- BSA in PBS-0.05% Tween-20 (v/v), PBST, pH 7.4) and washed. Individual sera samples,
- diluted 1:100 in blocking buffer, were added in duplicate to antigen-coated wells and
- incubated for 1 hr at 37°C. After washing five times with PBST, the secondary antibody HRP
- goat anti-human IgG (Fc specific) (Sigma-Aldrich) was added (1:15,000), and the plates were
- incubated for 1 hr at 37°C. After washing five times, TMB substrate (3,3',5,5'-
- 237 Tetramethylbenzidine Liquid Substrate Supersensitive, Sigma-Aldrich) was added to each
- well. Following a three-minute incubation the reaction was stopped with 2 N sulphuric acid
- and plates read at 450 nm in a plate reader (PolarStar). The background value was discounted
- 240 from the blanks and a cut-off (CO) value for each ELISA test was calculated from the
- 241 average of all the negative control samples plus three standard deviations. The average OD
- 242 (450 nm) obtained for each sample tested was divided by the cut-off of the test. Values >1
- 243 were considered SARS-CoV-2 positive in the test. Values <1 were negative SARS-CoV-2 in
- the test. Data were analysed using Prism 5 (Graphpad).

The commercially available Abbott ARCHITECT SARS-CoV-2 IgG ELISA test was
 performed according manufacturer's instructions.

247

# Assessing the antibody response of COVID-19 hospitalized patients using the dual antigen SARS-CoV-2 ELISA

250 Plasma samples of hospitalized patients with confirmed or suspected COVID-19 infection

251 were tested for the presence of IgG antibodies to Npro and S2Frag using our dual SARS-

252 CoV-2 ELISA assays (see section above). Individual plasma samples, diluted 1:100 in

blocking buffer, were added in duplicate into antigen-coated wells and incubated for 1 h at

254 37°C. The ELISA assays were developed as described above. The average OD (450 nm)

obtained for each sample tested was divided by the cut-off calculated for the test. Values > 1

were considered SARS-CoV-2 positive in the test. Values <1 were negative SARS-CoV-2 in

the test. Data were analysed using Prism 5 (Graphpad).

258

# 259 Statistical analyses

Statistical analysis was carried out using GraphPad Prism version 5. Differences between
negative controls and positive controls were analysed using an unpaired t-test. Correlation
between Npro and S2Frag ELISA tests or Abbott ARCHITECT SARS-CoV-2 IgG ELISA
test and our ELISA tests were aanalysed using Spearman's rank test with 95% confidence
intervals.

265

# 266 **RESULTS**

# 267 Isolation and solubilisation of SARS-CoV-2 recombinant proteins

268 Recombinant proteins were successfully expressed in *E. coli* BL21 cells; however, spike

269 protein and its various subunits were associated with insoluble inclusion bodies. By

employing a protocol using 1% SDS the inclusion bodies were solubilised and the various

271 proteins purified at ~1 mg/L of culture (Fig 2). The solubilisation and isolation of S2Frag is

shown in Fig 2A and B. Residual insoluble Npro was present in post-lysis recombinant *E*.

273 *coli* cell pellets. However, high level and soluble Npro expression was observed (yield: 3

274 mg/L) following affinity chromatography (Fig 2C). High sensitivity proteomic analysis

confirmed 53% and 68% sequence coverage for the Npro and S2frag recombinant antigens,
respectively (Supplementary Fig S1).

277

# ELISA antibody test using Npro and S2Frag distinguishes positive and negative SARS CoV-2 infected individuals

280 As part of the development and optimization of the in-house ELISA developed with the recombinant Npro and S2Frag, an appropriate cut-off point for each antigen was established 281 282 using 37 negative control human samples collected pre-COVID-19 pandemic (in 2018). Then, 42 SARS-CoV-2 qRT-PCR positive samples were screened using both Npro-ELISA 283 284 and S2Frag-ELISA. This screening showed that all 42 individuals assessed generated significant levels of IgG antibodies against both Npro and S2Frag proteins (Fig 3). Notably, 285 286 infected individuals showed an average antibody response to Npro that was consistently higher than the reactivity against S2Frag. Notwithstanding, both Npro and S2Frag could be 287 employed to distinguish positive and negative SARS-CoV-2 infected individuals. 288

Examining the performance of the Npro-ELISA, we deemed 36 (85.7%) samples as positive infected individuals. When these samples were tested with the S2Frag ELISA assay, 37 (88%) positive samples were identified. However, by combining the results of both ELISA tests, the number of positive samples was 40 (95.2%) because not all individuals produced antibodies against both Npro and S2Frag (Fig 4A, Table 1).

Serum samples from 98 healthcare workers suspected of exposure to SARS-CoV-2
were also screened in both ELISAs. Of these, 12 (12.2%) were detected as positive using
only the Npro ELISA (Fig 4B and Table 1) while 14 (14.3%) were deemed positive when the
S2Frag ELISA results were considered together with the results of the Npro ELISA.

298

# 299 Western blot analysis of SARS-CoV-2 positive serum samples

300 Western blot analysis using purified recombinant Npro and S2Frag proteins was performed

301 on all serum samples. This analysis confirmed infectivity of all individuals that were deemed

302 positive by ELISA. However, a wide range of reactivity was observed between patients,

303 which correlated with our ELISA observations showing that some patients produced

antibodies reactive with both Npro and S2Frag while others produced antibodies that reacted
with either Npro or S2Frag (see Fig 5 for representative Western blots).

306

# Comparison of the Npro and S2Frag ELISAs with a commercially available antibody test

In order to assess the sensitivity of the Npro and S2Frag ELISA tests against a commercially
available test, serum samples were tested in parallel using the Abbott ARCHITECT ELISA
(ARCHITECT SARS-CoV-2) which employs Npro as its antigen (Fig 6). Using the 42 qRTPCR-confirmed positive serum samples, the data showed complete agreement between the

Abbott ARCHITECT and the Npro ELISA test developed in this study (i.e. 85.4%

sensitivity) (Fig 6A). However, four patients that were negative and two that were positive by

both these tests showed a contrasting result when evaluated by the S2Frag-ELISA (Fig 6B).

Combining the data for the Npro-ELISA and S2Frag-ELISA tests increased the sensitivity of

317 detection to 95.2% (Table 1).

When the ARCHITECT test was employed to screen plasma samples from the 98 healthcare workers suspected of exposure to SARS-CoV-2 only six (6.1%) of these samples proved positive for SARS-CoV-2. In contrast, 14 (14.3%) individuals were identified as positive using our in-house ELISA tests (Fig 6C and D and Table 1).

322

# 323 Antibody responses to SARS-CoV-2 antigens in COVID-19 hospitalized patients

324Plasma samples from COVID-19 hospitalized patients were tested for specific antibodies

against our in-house Npro and S2Frag-ELISA tests. Two samples of each patient, at different

time-points after the onset of symptoms, were assessed and compared for their levels of

antibodies against Npro and S2Frag (Fig 7). The data shows that COVID-19 hospitalized

individuals develop strong antibody response to both Npro and S2Frag. However, the level of

- antibody to each antigen is very distinct. The OD/CO values obtained to the Npro were
- consistently higher than to the S2Frag (Medium OD/CO Npro= 8.46 and S2Frag= 2.09).
- 331 Moreover, antibodies to Npro could be detected from day seven after onset of symptoms,
- whilst antibodies to S2Frag were only detected from day 11 (Supplementary Table S1).
- 333 Nevertheless, from day 15 after onset of symptoms, all individuals assessed showed strong
- antibody response to both SARS-CoV-2 antigens.

When considering the number of days after onset of symptoms in relation to the 335 OD/CO values, our data show that COVID-19 patients reached their highest antibody levels 336 to virus antigens between day 15 and 21 after onset of symptoms. Surprisingly, from day 22 337 the antibody responses to both Npro and S2frag begin to decline (Fig 7A and B). Since the 338 S2Frag stimulates a weaker response, specific antibodies to this antigen dropped to levels 339 close to the cut-off of the test within approximately seven weeks; the average S2Frag OD/CO 340 values for the first plasma samples obtained between days 15-21 and between 28-35 were 341 3.64 and 1.34, respectively. These values varied less when we assessed the responses to 342 343 Npro; OD/CO values varied from 12.67 to 12.2 when the same intervals were considered (Supplementary Table S1). 344

345

#### 346 **DISCUSSION**

Individuals infected with coronaviruses mount an immune response with protective 347 neutralizing antibodies for a period of time [23]. Recent studies have shown that neutralizing 348 antibodies to SARS-CoV-2 proteins can be detected in all infected individuals by day 14 after 349 onset of symptoms [8, 24]. Both the Spro and Npro are highly immunogenic structural 350 proteins capable of generating such an antibody response [13, 25-27]. Upon infection, the 351 Spro is readily presented to the host as part of the invasion process. In contrast, the Npro 352 integrates with the host cell nucleus and nucleolus and is abundantly expressed during 353 354 infection, playing important roles in the transcription and replication of viral RNA and 355 packaging of the encapsulated genome into virions [28, 29].

Since the start of the COVID-19 global pandemic, Spro and Npro have been extensively used to develop the antibody tests to diagnose past-infection by SARS-CoV-2. As antibody tests identify historic infections, they are a highly prized tool for epidemiological studies that track the spread of the virus within the community and for estimating herd immunity. However, independent and more extensive assessment of these tests has highlighted serious issues with their sensitivity that result in up to 20% false negativity [17, 18].

It has been shown that antibodies targeted against Npro appear earlier than those against Spro [30], offering an explanation as to why Npro is the antigen of choice in most commercially available tests. To understand how individuals naturally infected with SARS-CoV-2 respond to the main viral antigens, six viral proteins were recombinantly expressed: 367 the full-length Spro and four different sub-segments, i.e. S1Frag, S2Frag, S2Prime and RBD (Fig 1), and the Npro. Through Western blot analysis, variability in the immune response to 368 each antigen between individuals was observed (Supplementary Fig S2). At least 85% of the 369 COVID-19 positive individuals tested in this study showed a consistent and strong antibody 370 371 response to Npro. However, our data shows that 7% of the COVID-19 non-hospitalized individuals confirmed positive by qRT-PCR were misdiagnosed as negative when using 372 either our in-house Npro-ELISA or the commercial ARCHITECT test, demonstrating that 373 some individuals do not produce antibodies to Npro or, alternatively, had not produced these 374 375 at the time of sampling.

Despite previous reports stating that the receptor-binding domain (RBD) of the Spro 376 is highly immunogenic and the target of many neutralizing antibodies, the RBD protein 377 378 produced in this study was not immunogenic (Supplementary Fig S2) [31-33]. It is worth 379 noting that our antigens were recombinantly produced using a prokaryotic E. coli system, 380 while the immunogenic recombinant RBD produced by Amanat et al. [15] was expressed in mammalian cells. This could have resulted in proteins with different antigenic properties that 381 382 affect the ability of host antibodies to recognize the antigen. Nevertheless, our study agrees with Robbiani et al. [34], who observed that convalescent plasma samples from individuals 383 384 who recover from COVID-19 do not contain high levels of RBD-specific neutralizing antibodies. 385

Conversely, the full-length Spro was consistently recognized by antibodies from 386 individuals infected by SARS-CoV-2 [32, 35, 36]. Although the subdomain S1 protein 387 388 (S1Frag), containing the RBD, is the most common fragment of the Spro used in commercial serological tests, our study found that a stronger immune response was directed against the 389 subdomain S2 protein (S2Frag); 38 of the 42 (90.5%) individuals that were SARS-CoV-2 390 RT-PCR-positive elicited antibodies to the S2Frag, indicating the diagnostic value of the 391 392 domain. However, based on the OD/CO values obtained, COVID-19 hospitalized and nonhospitalized positive individuals mounted stronger immune response against Npro, indicating 393 that S2Frag is less immunogenic. 394

It was reported that during COVID-19 infection a decrease in the number of viral particles coincides with the appearance of neutralizing antibodies [37], although the longevity of such antibodies is debatable. Antibody titres to SARS-CoV-2 proteins were demonstrated to remain elevated for variable periods, seven days to more than 48 days, and serve to protect

the individual against reinfection [8, 24]. In our study we found that infected individuals did
not sustain high antibody levels to SARS-CoV-2 antigens for long periods, and even
individuals that developed severe disease and required intensive care exhibited antibody
declines, mainly those specific to S2Frag, after three weeks (Fig 7 A and B and
Supplementary Table S1). As both anti-Spro and anti-Npro IgG antibodies have been
observed to neutralize SARS-CoV-2 [38], our tests may be of use for assessing protection
after infection or immunization.

By performing a dual ELISA with Npro and S2Frag we detected anti-viral antibodies 406 in 40 out of 42 PCR-positive individuals. Follow-up Western Blot analysis of the two 407 408 negative samples by ELISA, indicated that one individual had no antibodies against the viral antigens (Study code C11, supplementary Fig S4), whilst the second patient had only a weak 409 response to S2Frag (Study code C86, supplementary Fig S4). The results obtained for C11 410 suggest that the patient received a false-positive qRT-PCR result, though it is important to 411 412 consider that little is known about seroconversion during SARS-CoV-2 infection. While some patients may seroconvert, others might develop low antibody titres that wane within a 413 short period of time, generating false-negative results [15]. On the other hand, the analytical 414 sensitivity of SARS-CoV-2 qRT-PCR tests is 80% [39, 40], leaving a large potential for false 415 416 negative results that we certainly observed in our study. Among the ten SARS-CoV-2 qRT-PCR negative hospitalized patients we evaluated, four tested positive for antibodies to Npro 417 and/or S2Frag in our ELISAs (Supplementary Table S1). Our results indicate that targeting 418 the antibody response against both Npro and S2Frag in serological diagnostic tests increases 419 420 the sensitivity of detection of true positive SARS-CoV-2 infection and, therefore, represents an important strategy to improve COVID-19 diagnosis. 421

Our ELISAs results also revealed that ~17% of the 42 qRT-PCR-positive individuals 422 recognize either Npro or S2Frag antigen only; ~7% of the individuals exclusively recognized 423 Npro while 10% only recognised S2Frag alone (Fig 4A). These antigen-selective immune 424 responses were confirmed using Western blot analysis (Fig 5). A similar observation was 425 reported by Liu et al. [35], who evaluated the IgM and IgG antibody responses of 214 426 COVID-19 positive patients; Npro- or Spro-based ELISA resulted in positive rates of 80.4% 427 and 82.2%, respectively, whereas together these detected 86.9% (186 patients). While these 428 429 results indicate the diagnostic value of the antigens association, the differential reactivity of the serum samples with Npro and Spro was not assessed in that particular study [35]. 430

431 When we analysed the antibody response of 15 patients that were hospitalized with COVID-19 we found that the Npro OD/CO values for ICU and non-ICU patients were 10.34 432 and 6.82 (P < 0.05), respectively (Supplementary Table S1), while the values for S2Frag did 433 not vary significantly between each group (OD/CO = 1.93 and 2.22, respectively). Sun et al. 434 435 [41] also found that anti-Npro IgG antibodies were significantly higher in ICU patients compared to non-ICU patients. Therefore, anti-Npro antibodies could be an indicator of 436 disease severity, although we did not find a correlation between antibody levels and age of 437 the patients in our study (Supplementary Fig S3). 438

In the present study, we compared our ELISAs results with the commercially-439 available immunoassay ARCHITECT (Abbott), which detects antibody response solely to 440 Npro. The results of our in-house Npro-ELISA agreed 100% with the ARCHITECT test 441 when we screened the 42 gRT-PCR positive sample set. However, only 6 of the 98 healthcare 442 workers suspected of exposure to SARS-CoV-2 were deemed positive by ARCHITECT test, 443 444 compared to 12 identified using our Npro-ELISA. This discrepancy rose to 14 when we employed the Npro and S2Frag dual ELISA, results which were confirmed by Western Blot 445 analysis (Fig 5 and Supplementary Fig S4). A recent longitudinal seroprevalence study found 446 a 95% prevalence of anti-SARS-CoV-2 antibodies in staff working in two hospitals in Ireland 447 who had previously confirmed infection by PCR. Moreover, 16% of those with detectable 448 antibodies reported never having experienced COVID-19 symptoms. Noteworthy, the study 449 450 used primarily ARCHTECT test that was complemented with the Wantai SARS-CoV-2 AB ELISA (Fortress Diagnostics) and the Roche anti-SARS-CoV-2 immunoassay, improving the 451 452 detection of positive cases and revealing that the real seroprevalence amongst the hospitals' workers is between 2 and 5% higher than the number given by PCR diagnosis [11]. The 453 importance of the diagnostic methods applied was further assessed by Rikhtegaran Tehrani et 454 455 al. [36], which investigated 300 pre-epidemic samples and 100 PCR-confirmed COVID-19 samples using commercial tests such as EDI™ Novel Coronavirus COVID-19 ELISA, 456 Euroimmun Anti-SARS-CoV-2 ELISA and PP® COVID-19 IgM/IgG System. This study 457 found that their in-house Spro and Npro-based ELISAs performed with the highest sensitivity 458 and specificity. In all, our results indicate that our in-house quantitative ELISA performs 459 better than the non-quantitative ARCHITECT tests using a single Npro protein and can be 460 improved by running the dual ELISA assay with S2Frag. 461

#### 463 CONCLUSIONS

464 COVID-19 serological testing in clinical settings relies on ELISA assays, which can
465 be both qualitative and quantitative and thus a valuable tool in diagnosing past such
466 infections [40]. However, the preference for rapid tests and the deficient performance of most
467 commercially available SARS-CoV-2 serological tests may pose a serious risk to diagnostic
468 efficacy [8, 17, 18]. Therefore, quantitative ELISA tests such as those developed in this study
469 could be essential to understand the dynamic of individual antibody response to the virus and,
470 consequently, plan appropriate measures of control during the COVID-19 pandemic.

In this study we evaluated two ELISA tests for detecting IgG antibodies to Npro and 471 to the subdomain 2 of the Spro (S2Frag), and showed that by combining the tests we can 472 improve the serological diagnosis of COVID-19 cases. Furthermore, we showed the 473 474 applicability of the tests using plasma samples from hospitalized patients. Quantitative ELISA tests would allow us to assess antibody levels that are associated with protection or 475 indicate a more recent or historic infection. As serological diagnostics of COVID-19 patients 476 determine population-level surveillance and complement qRT-PCR and antigen tests, the 477 optimization of antibody tests is critical to control the COVID-19 pandemic. 478

479

#### 480 ACKNOWLEDGEMENTS

- 481 Dr David Fitzpatrick is acknowledged for expertise regarding Npro sequence identification482 for protein expression.
- 483 Dr Jean Dunne and Dr Niall Conlon (Department of Immunology St James's Hospital,
- 484 James's Street, Dublin Ireland), Ms Fiona O'Rourke, Ms Yvonne Lynagh, Ms Martina Kelly
- and Dr Brendan Crowley (Department of Microbiology St James's Hospital, James's Street,
- 486 Dublin Ireland) for their contributions recruiting samples, collecting data from Healthcare
- 487 workers (St James's Hospital) and analysing the samples.

488

## 489 FINANCIAL SUPPORT

- 490 This work was supported by the Science Foundation Ireland (SFI) COVID-19 Rapid
- 491 Response Funding Call, proposal ID 20/COV/0023 and 20/COV/0048. Mass spectrometry

- 492 facilities were funded by a Science Foundation Ireland infrastructure award to SD
- $493 \quad (\underline{12/RI/2346(3)}).$
- 494

# 495 CONFLICT OF INTEREST

- 496 None.
- 497

# 498 SUPPLEMENTARY FILE

- 499 Supplementary file data archive available on the Cambridge University Press Cambridge
- 500 Core website.

501

# 502 **REFERENCES**

- 503 (1) Zhu N, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N
   504 Engl J Med 2020; 382(8): 727-733.
- 505 (2) Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. *Nat Rev* 506 *Microbiol* 2019; 17(3): 181-192.
- 507 (3) Organization WH. Coronavirus disease (COVID-19) pandemic. In:
- 508 <u>https://covid19.who.int/</u>, 2021.
- 509 (4) Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor
  510 usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat Microbiol* 2020; 5(4):
  511 562-569.
- 512 (5) **V'Kovski P, et al.** Coronavirus biology and replication: implications for SARS-CoV-513 2. *Nat Rev Microbiol* 2021; **19**(3): 155-170.
- 514 (6) Corman VM, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time
   515 RT-PCR. *Euro Surveill* 2020; 25(3).
- 516 (7) **Zhang W, et al.** Molecular and serological investigation of 2019-nCoV infected
- patients: implication of multiple shedding routes. *Emerg Microbes Infect* 2020; 9(1): 386389.
- 519 (8) Kevadiya BD, et al. Diagnostics for SARS-CoV-2 infections. *Nat Mater* 2021.
- 520 (9) Coronaviridae Study Group of the International Committee on Taxonomy of V.
- 521 The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV 522 and naming it SARS-CoV-2. *Nat Microbiol* 2020; **5**(4): 536-544.
- 523 (10) Kohmer N, et al. The Comparative Clinical Performance of Four SARS-CoV-2
- 524 Rapid Antigen Tests and Their Correlation to Infectivity In Vitro. *J Clin Med* 2021; **10**(2).
- 525 (11) Niamh Allen UNR, Niall Conlon, Annamaria Ferenczi, Antonio Isidro Carrion
- 526 Martin,, Lisa Domegan CW, Lorraine Doherty, Catherine Fleming, Colm Bergin. Prevalence
- 527 of Antibodies to SARS-CoV-2 in Irish Healthcare Workers PRECISE Study. In: (HPSC)
- 528 HPSC, ed. <u>https://www.hpsc.ie/a-</u>
- 529 <u>z/respiratory/coronavirus/novelcoronavirus/research/precise/</u>, 2021.

- 530 (12) Guo L, et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus
  531 Disease (COVID-19). *Clin Infect Dis* 2020; **71**(15): 778-785.
- 532 (13) **Zhao J, et al.** Antibody Responses to SARS-CoV-2 in Patients With Novel
- 533 Coronavirus Disease 2019. *Clin Infect Dis* 2020; **71**(16): 2027-2034.
- 534 (14) Long QX, et al. Clinical and immunological assessment of asymptomatic SARS-
- 535 CoV-2 infections. *Nat Med* 2020; **26**(8): 1200-1204.
- 536 (15) Amanat F, et al. A serological assay to detect SARS-CoV-2 seroconversion in
  537 humans. *Nat Med* 2020; 26(7): 1033-1036.
- 538 (16) Kissler SM, et al. Projecting the transmission dynamics of SARS-CoV-2 through the
  539 postpandemic period. *Science* 2020; 368(6493): 860-868.
- 540 (17) Schnurra C, et al. Comparison of the diagnostic sensitivity of SARS-CoV-2
- nucleoprotein and glycoprotein-based antibody tests. *J Clin Virol* 2020; **129**: 104544.
- 542 (18) Armstrong S. Testing times for the government's favoured antibody kit. *BMJ* 2020;
  543 371: m4440.
- 544 (19) Mulchandani R, et al. Accuracy of UK Rapid Test Consortium (UK-RTC) "AbC-19
   545 Rapid Test" for detection of previous SARS-CoV-2 infection in key workers: test accuracy
- 546 study. *BMJ* 2020; **371**: m4262.
- 547 (20) Deeks JJ, et al. Antibody tests for identification of current and past infection with
  548 SARS-CoV-2. *Cochrane Database Syst Rev* 2020; 6: CD013652.
- 549 (21) Schlager B, Straessle A, Hafen E. Use of anionic denaturing detergents to purify 550 insoluble proteins after overexpression. *BMC Biotechnol* 2012; **12**: 95.
- Waldron R, et al. Characterisation of three novel beta-1,3 glucanases from the
  medically important house dust mite Dermatophagoides pteronyssinus (airmid). *Insect Biochem Mol Biol* 2019; 115: 103242.
- 554 (23) **Liu W, et al.** Two-year prospective study of the humoral immune response of patients 555 with severe acute respiratory syndrome. *J Infect Dis* 2006; **193**(6): 792-795.
- 556 (24) Padoan A, et al. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients
  557 with COVID-19: A longitudinal study. *Clin Chim Acta* 2020; 507: 164-166.
- 558 (25) **Woo PC, et al.** Differential sensitivities of severe acute respiratory syndrome (SARS) 559 coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA) and SARS
- coronavirus nucleocapsid protein ELISA for serodiagnosis of SARS coronavirus pneumonia.
   *J Clin Microbiol* 2005; 43(7): 3054-3058.
- 562 (26) Guan M, et al. Recombinant protein-based enzyme-linked immunosorbent assay and
  563 immunochromatographic tests for detection of immunoglobulin G antibodies to severe acute
  564 respiratory syndrome (SARS) coronavirus in SARS patients. *Clin Diagn Lab Immunol* 2004;
  565 11(2): 287-291.
- 566 (27) Chen S, et al. Double-antigen sandwich ELISA for detection of antibodies to SARS567 associated coronavirus in human serum. *Eur J Clin Microbiol Infect Dis* 2005; 24(8): 549-
- 568 553.
- 569 (28) Hurst KR, Koetzner CA, Masters PS. Identification of in vivo-interacting domains
  570 of the murine coronavirus nucleocapsid protein. *J Virol* 2009; 83(14): 7221-7234.
- 571 (29) Cui L, et al. The Nucleocapsid Protein of Coronaviruses Acts as a Viral Suppressor
- 572 of RNA Silencing in Mammalian Cells. *J Virol* 2015; **89**(17): 9029-9043.
- 573 (30) Burbelo PD, et al. Detection of Nucleocapsid Antibody to SARS-CoV-2 is More
  574 Sensitive than Antibody to Spike Protein in COVID-19 Patients. *medRxiv* 2020.
- 575 (31) **Du L, et al.** Recombinant receptor-binding domain of SARS-CoV spike protein
- 576 expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and 577 protective immunity. *Virology* 2009; **393**(1): 144-150.
- 578 (32) **Berry JD, et al.** Neutralizing epitopes of the SARS-CoV S-protein cluster
- independent of repertoire, antigen structure or mAb technology. *MAbs* 2010; **2**(1): 53-66.

580 (33) Premkumar L, et al. The receptor binding domain of the viral spike protein is an
581 immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. *Sci*582 *Immunol* 2020; 5(48).

(34) Robbiani DF, et al. Convergent antibody responses to SARS-CoV-2 in convalescent
individuals. *Nature* 2020; 584(7821): 437-442.

Liu W, et al. Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked
 Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2. *J Clin Microbiol* 2020; 58(6).

588 (36) Rikhtegaran Tehrani Z, et al. Performance of nucleocapsid and spike-based SARS 589 CoV-2 serologic assays. *PLoS One* 2020; 15(11): e0237828.

590 (37) Bullard J, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. *Clin* 591 *Infect Dis* 2020.

592 (38) Lumley SF, et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health
593 Care Workers. *N Engl J Med* 2021; 384(6): 533-540.

594 (39) America LCo. EMERGENCY USE AUTHORIZATION (EUA) SUMMARY

595 COVID-19 RT-PCR TEST. In. <u>https://www.fda.gov/media/136151/download</u>, 2020.

596 (40) Khalaf K, et al. SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and

597 Treatment. *Front Immunol* 2020; **11**: 570927.

598 (41) Sun B, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19
 599 patients. *Emerg Microbes Infect* 2020; 9(1): 940-948.

600

601

602

603

604

605

606

607

608

609

610

611

612

613

# 614 Tables

615

- **Table 1**. Comparison of the performance of the commercially available Abbott ARCHITECT
- 617 test and the ELISA developed in the current study.

	Commercial	Npro	S2Frag	Npro/S2Frag			
	test	ELISA IgG	ELISA IgG	ELISA IgG			
Samples confirmed SARS-CoV-2 positive by RT-PCR							
N Positive	35 (85.4%)	36 (85.7%)	37 (88%)	40 (95.2%)			
N Negative	6 (14.6%)	6 (14.3%)	5 (12%)	2 (4.8%)			
N Total	41	42	42	42			
Correlation coefficient	-	1.0	0.27	0.55 (p ≤ 0,01)			
Samples suspected for SARS-CoV-2							
N Positive	6 (6.1%)	12 (12.2%)	6 (6.1%)	14 (14.3%)			
N Negative	92 (93.9%)	86 (87.8%)	92 (93.9%)	84 (85.7%)			
N Total	98	98	98	98			
<b>Correlation</b> coefficient	-	0.42 (p ≤ 0,01)	$0.47(p \le 0.01)$	0.38 (p ≤ 0,01)			

618

# 620 Legends for Figures

621

622	Figure 1. Primary sequence of the SARS-CoV-2 proteins. A: The amino acid sequence of
623	the Spike protein (1273 residues). Residues in bold and underlined represent the signal
624	peptide. Residues highlighted in black (319-542) represent the receptor-binding domain
625	(RBD). Underlined residues delineate the S1-fragment (S1Frag, residue 1-686). Residues in
626	red show the polybasic cleavage site that separates the S1 and S2-fragments (residue 686).
627	Residues highlighted in grey comprise the S2-fragment (S2Frag, residue 687-1273). Residues
628	highlighted in yellow and bold (residue 815) show the beginning of S2Prime sequence
629	(residue 816-1273). Residues in bold represent the transmembrane and endo-domain (1214-
630	1273). B: Schematic representation of the Spike protein and its various portions
631	recombinantly expressed in the present study (see [15]). C: Nucleocapsid protein sequence
632	(Npro, residue 2-1269) used for recombinant expression in <i>Echerichia coli</i> .
622	
633	
633	Figure 2. Recombinant production and purification of Spike protein fragment 2
633 634 635	<b>Figure 2. Recombinant production and purification of Spike protein fragment 2</b> ( <b>S2Frag).</b> A: Solubilisation of the S2Frag protein. P1, <i>E. coli</i> pellet after induction with IPTG
633 634 635 636	<b>Figure 2. Recombinant production and purification of Spike protein fragment 2</b> ( <b>S2Frag</b> ). A: Solubilisation of the S2Frag protein. P1, <i>E. coli</i> pellet after induction with IPTG for 4 hr at 30°C; S1, supernatant containing soluble proteins after pellet digestion with 0.1
633 634 635 636 637	Figure 2. Recombinant production and purification of Spike protein fragment 2         (S2Frag). A: Solubilisation of the S2Frag protein. P1, <i>E. coli</i> pellet after induction with IPTG         for 4 hr at 30°C; S1, supernatant containing soluble proteins after pellet digestion with 0.1         mg/mL of lysozyme; S2, supernatant containing insoluble proteins after pellet digestion with
633 634 635 636 637 638	Figure 2. Recombinant production and purification of Spike protein fragment 2(S2Frag). A: Solubilisation of the S2Frag protein. P1, <i>E. coli</i> pellet after induction with IPTGfor 4 hr at 30°C; S1, supernatant containing soluble proteins after pellet digestion with 0.1mg/mL of lysozyme; S2, supernatant containing insoluble proteins after pellet digestion withlysis buffer containing 1% SDS. B: S2Frag purification over Ni-NTA beads column. ST,
633 634 635 636 637 638 639	Figure 2. Recombinant production and purification of Spike protein fragment 2 (S2Frag). A: Solubilisation of the S2Frag protein. P1, <i>E. coli</i> pellet after induction with IPTG for 4 hr at 30°C; S1, supernatant containing soluble proteins after pellet digestion with 0.1 mg/mL of lysozyme; S2, supernatant containing insoluble proteins after pellet digestion with lysis buffer containing 1% SDS. B: S2Frag purification over Ni-NTA beads column. ST, supernatant total diluted; FT, column flow through; W, washes; E, eluted protein; M,
<ul> <li>633</li> <li>634</li> <li>635</li> <li>636</li> <li>637</li> <li>638</li> <li>639</li> <li>640</li> </ul>	Figure 2. Recombinant production and purification of Spike protein fragment 2 (S2Frag). A: Solubilisation of the S2Frag protein. P1, <i>E. coli</i> pellet after induction with IPTG for 4 hr at 30°C; S1, supernatant containing soluble proteins after pellet digestion with 0.1 mg/mL of lysozyme; S2, supernatant containing insoluble proteins after pellet digestion with lysis buffer containing 1% SDS. B: S2Frag purification over Ni-NTA beads column. ST, supernatant total diluted; FT, column flow through; W, washes; E, eluted protein; M, Molecular weight marker in kDa. C. 4-20% SDS-PAGE analysis of recombinant SARS-CoV-
<ul> <li>633</li> <li>634</li> <li>635</li> <li>636</li> <li>637</li> <li>638</li> <li>639</li> <li>640</li> <li>641</li> </ul>	Figure 2. Recombinant production and purification of Spike protein fragment 2 (S2Frag). A: Solubilisation of the S2Frag protein. P1, <i>E. coli</i> pellet after induction with IPTG for 4 hr at 30°C; S1, supernatant containing soluble proteins after pellet digestion with 0.1 mg/mL of lysozyme; S2, supernatant containing insoluble proteins after pellet digestion with lysis buffer containing 1% SDS. B: S2Frag purification over Ni-NTA beads column. ST, supernatant total diluted; FT, column flow through; W, washes; E, eluted protein; M, Molecular weight marker in kDa. C. 4-20% SDS-PAGE analysis of recombinant SARS-CoV- 2 nucleocapsid protein (Npro) following HisTrap HP columns.

#### 643 Figure 3. The determination of cut-off values for positive and negative results by

644 **ELISA.** Forty-two sera samples from patients with a positive SARS-CoV-2 diagnosis by

- 645 RT-PCR and 37 sera samples stored in a blood bank prior to SARS-CoV-2 were tested by
- ELISA to determine the cut-off values for a positive or negative result for antibodies against
- 647 Npro or S2frag. Pos: Positive. Neg: Negative.

648

- 649 Figure 4. Antibodies against Npro or S2frag detected in sera from individuals
- 650 confirmed positive for SARS-CoV-2 infection by RT-PCR, or suspected of SARS-CoV-2
- 651 infection. (A) Sera from 42 RT-PCR positive SARS-CoV-2 patients were tested for
- antibodies against Npro and S2Frag by the ELISA antibody test developed in this study. R
- 653 square: 0.3132. (B) Sera from 98 suspected SARS-CoV-2 individuals were tested for
- antibodies against Npro and S2Frag. R square: 0.4704. ( sera were negative for antibodies
- against both Npro and S2frag by ELISA; A sera were positive for antibodies against Npro
- only by ELISA; ♦ sera were positive for antibodies against S2frag only by ELISA; sera
- 657 were positive for antibodies against both Npro and S2frag by ELISA). Individual results for
- Npro and S2Frag ELISA presented as Optical density (OD 450 nm) divided by the calculated
- 659 cut-off (CO). The cut-off value for each antigen is indicated by the dotted line.

660

#### 661 Figure 5. Western blots representative of samples showing the presence and absence of

662 antibodies to Npro and S2frag in individuals positive for SARS-CoV-2. Sera were

- assayed by Western blot to detect antibodies against Npro (N) and S2frag (S). A:
- Recombinant proteins resolved in a 4-12% SDS-PAGE and stained with Coomassie-blue. B:
- 665 Western Blot control performed using a monoclonal mouse anti-polyhistidine antibody

(1:10,000) (Sigma-Aldrich) as a primary antibody followed by incubation with a secondary
antibody alkaline phosphatase conjugated goat to mouse-anti-IgG diluted 1:5,000 (SigmaAldrich). C-F: The antibodies response to Npro and S2frag of different individuals positive
for SARS-CoV-2. Individual ELISA tests results are shown for each sample as positive or
negative for SARS-CoV-2.

671

#### **Figure 6. Contrasting results obtained by the commercially available Abbott**

#### 673 ARCHITECT antibody test and the ELISA antibody test developed in the current

674 study. A and B, the agreement of SARS-CoV-2 diagnostic of 42 RT-PCR positive SARS-

675 CoV-2 individuals assessed using Npro and S2frag ELISA test or the commercially available

676 Abbott ARCHITECT antibody test. C and D, the agreement of SARS-CoV-2 diagnostic of 98

677 suspected SARS-CoV-2 individuals assessed using Npro and S2frag ELISA test or the

678 commercially available Abbott ARCHITECT antibody test. Samples were categorised

according to the positive or negative result of the commercially available Abbott

680 ARCHITECT test. Individual results for Npro and S2Frag ELISA test presented as optical

density (OD 450 nm) divided by the calculated cut-off (CO) (sera were negative for

antibodies by ELISA; • sera were positive for antibodies by ELISA). The cut-off value for

each antigen is indicated by the dotted line.

684

#### Figure 7. Variation of the antibody response to SARS-CoV-2 antigens in COVID-19

686 hospitalised patients. A, COVID-19 hospital patients plasma samples were tested to their

687 immune response to: (A) Nucleocapsid protein (Npro) and (B) Subunit 2 of spike protein

688 (S2Frag) in ELISA assays. The antibody response of each patient was assessed at two

689	different time points. Samples were categorised according to the day after onset of symptoms
690	the first plasma sample was obtained, represented in the graphic by periods. The antibody
691	levels (OD/CO) of the two samples are compared in the graphic: Triangles represent the first
692	sample and circles represent the second sample collected. Patient code is presented next to
693	the antibody level of the second sample. In between parentheses the number of days after
694	onset of symptoms that the second plasma sample was obtained. OD: Optical density at 450
695	nm. CO: Cut-off calculated for the specific test. The cut-off value for each antigen is
696	indicated by the dotted line.
697	
698	
699	
700	
701	
702	
702	
703	
704	
705	
706	
/07	
708	

**MFVFLVLLPLVSSQC**VNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSN VTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNN ATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGK QGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALH RSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSF TVEKGIYQTSNF<mark>RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVL</mark> YNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDF TGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYF PLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFN<mark>FNGLTGTG</mark> VLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQ DVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASY QTQTNSPRAR SVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVD CTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFG GFNFSQILPDPSKPSKR<mark>SF</mark>IEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTV LPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS RLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFC GKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWF VTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDV DLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKW**PWYIWLGFIAGLI** 

SDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHGK EDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAGL PYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGSQA SSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQQQ GQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKHW PQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAYKT FPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA





# 

С











ELISA TEST	Result			
Npro	Negative	Positive	Negativ	
S2Frag	Negative	Negative	Positiv	
Abbott	Positive	Negative	Negativ	

S Ν S Negative ve Negative /e Negative ve

F

Ε

D





![](_page_30_Picture_1.jpeg)